Evicenter
MarkdownMedical informationP&T meetings
AD109 (aroxybutynin-atomoxetine)

Obstructive sleep apnea

Also known as Oxnimbi
Manufacturer
Apnimed
Launch
Not announced
Last updated
183 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Positive airway pressure therapy

21 evidence topics · 14 sources

AASM guideline: PAP for excessive sleepiness (strong), impaired sleep-related quality of life (conditional), and comorbid hypertension (conditional)
SAVE: CPAP and cardiovascular events in OSA with established cardiovascular disease, OSA defined by a 4% oxygen desaturation index of at least 12

“The diagnosis of moderate-to-severe obstructive sleep apnea, which was defined as an oxygen desaturation index (the number of times per hour during the oximetry recording that the blood oxygen saturation level drops by ≥4 percentage points from baseline) of at least 12, was established with the use of a home sleep-study screening device (ApneaLink, ResMed) and was confirmed by review of the data at a central core sleep laboratory.” (opens the source at this quote in a new tab)

“In the CPAP group, the mean duration of adherence to CPAP therapy was 3.3 hours per night, and the mean apnea–hypopnea index (the number of apnea or hypopnea events per hour of recording) decreased from 29.0 events per hour at baseline to 3.7 events per hour during follow-up.” (opens the source at this quote in a new tab)

“After a mean follow-up of 3.7 years, a primary end-point event had occurred in 229 participants in the CPAP group (17.0%) and in 207 participants in the usual-care group (15.4%) (hazard ratio with CPAP, 1.10; 95% confidence interval, 0.91 to 1.32; P=0.34).” (opens the source at this quote in a new tab)

“CPAP significantly reduced snoring and daytime sleepiness and improved health-related quality of life and mood.” (opens the source at this quote in a new tab)

“Therapy with CPAP plus usual care, as compared with usual care alone, did not prevent cardiovascular events in patients with moderate-to-severe obstructive sleep apnea and established cardiovascular disease.” (opens the source at this quote in a new tab)

Adherence: 90-day adherence by the Medicare definition in a device manufacturer’s cloud database

“We assessed de-identified data from a large cloud database of positive airway pressure (PAP) users to examine adherence to therapy during the period 1-Oct-2014 to 31-Oct-2017.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“All Air10 platform PAP devices (ResMed Inc., San Diego, USA) have an on-board mobile communications chip which connects to the secure cloud infrastructure automatically.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“ResMed Corp, USA funded the study and their employees (JA, AB, CMN) contributed to the design and conduct of the study, analysis, and interpretation of the data and preparation of the manuscript for publication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The primary outcome was adherence, which was defined using the US Center for Medicare and Medicaid Services (CMS) definition (≥4 hours’ PAP use on 70% of nights in a consecutive 30-day period in the first 90 days of therapy).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The observed 90-day PAP adherence rate using the CMS definition was 75%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Prior studies suggest that up to 24% of patients may not fulfill their PAP prescription [14] and a proportion of patients may not even turn on their PAP machine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote